药物与微生物群相互作用的新评估系统

IF 23.7 Q1 MICROBIOLOGY iMeta Pub Date : 2024-05-07 DOI:10.1002/imt2.199
Tian-Hao Liu, Chen-Yang Zhang, Hang Zhang, Jing Jin, Xue Li, Shi-Qiang Liang, Yu-Zheng Xue, Feng-Lai Yuan, Ya-Hong Zhou, Xiu-Wu Bian, Hong Wei
{"title":"药物与微生物群相互作用的新评估系统","authors":"Tian-Hao Liu,&nbsp;Chen-Yang Zhang,&nbsp;Hang Zhang,&nbsp;Jing Jin,&nbsp;Xue Li,&nbsp;Shi-Qiang Liang,&nbsp;Yu-Zheng Xue,&nbsp;Feng-Lai Yuan,&nbsp;Ya-Hong Zhou,&nbsp;Xiu-Wu Bian,&nbsp;Hong Wei","doi":"10.1002/imt2.199","DOIUrl":null,"url":null,"abstract":"<p>The drug response phenotype is determined by a combination of genetic and environmental factors. The high clinical conversion failure rate of gene-targeted drugs might be attributed to the lack of emphasis on environmental factors and the inherent individual variability in drug response (IVDR). Current evidence suggests that environmental variables, rather than the disease itself, are the primary determinants of both gut microbiota composition and drug metabolism. Additionally, individual differences in gut microbiota create a unique metabolic environment that influences the in vivo processes underlying drug absorption, distribution, metabolism, and excretion (ADME). Here, we discuss how gut microbiota, shaped by both genetic and environmental factors, affects the host's ADME microenvironment within a new evaluation system for drug–microbiota interactions. Furthermore, we propose a new top-down research approach to investigate the intricate nature of drug–microbiota interactions in vivo. This approach utilizes germ-free animal models, providing foundation for the development of a new evaluation system for drug–microbiota interactions.</p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":null,"pages":null},"PeriodicalIF":23.7000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.199","citationCount":"0","resultStr":"{\"title\":\"A new evaluation system for drug–microbiota interactions\",\"authors\":\"Tian-Hao Liu,&nbsp;Chen-Yang Zhang,&nbsp;Hang Zhang,&nbsp;Jing Jin,&nbsp;Xue Li,&nbsp;Shi-Qiang Liang,&nbsp;Yu-Zheng Xue,&nbsp;Feng-Lai Yuan,&nbsp;Ya-Hong Zhou,&nbsp;Xiu-Wu Bian,&nbsp;Hong Wei\",\"doi\":\"10.1002/imt2.199\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The drug response phenotype is determined by a combination of genetic and environmental factors. The high clinical conversion failure rate of gene-targeted drugs might be attributed to the lack of emphasis on environmental factors and the inherent individual variability in drug response (IVDR). Current evidence suggests that environmental variables, rather than the disease itself, are the primary determinants of both gut microbiota composition and drug metabolism. Additionally, individual differences in gut microbiota create a unique metabolic environment that influences the in vivo processes underlying drug absorption, distribution, metabolism, and excretion (ADME). Here, we discuss how gut microbiota, shaped by both genetic and environmental factors, affects the host's ADME microenvironment within a new evaluation system for drug–microbiota interactions. Furthermore, we propose a new top-down research approach to investigate the intricate nature of drug–microbiota interactions in vivo. This approach utilizes germ-free animal models, providing foundation for the development of a new evaluation system for drug–microbiota interactions.</p>\",\"PeriodicalId\":73342,\"journal\":{\"name\":\"iMeta\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":23.7000,\"publicationDate\":\"2024-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.199\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iMeta\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/imt2.199\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

药物反应表型由遗传和环境因素共同决定。基因靶向药物的临床转化失败率较高,这可能是由于缺乏对环境因素的重视以及药物反应固有的个体差异性(IVDR)造成的。目前的证据表明,环境变量而非疾病本身是肠道微生物群组成和药物代谢的主要决定因素。此外,肠道微生物群的个体差异会形成独特的代谢环境,影响药物吸收、分布、代谢和排泄(ADME)的体内过程。在此,我们将讨论肠道微生物群是如何在药物与微生物群相互作用的新评价体系中,通过遗传和环境因素影响宿主的 ADME 微环境的。此外,我们还提出了一种新的自上而下的研究方法,用于研究药物与微生物群在体内相互作用的复杂性质。这种方法利用无菌动物模型,为开发药物与微生物群相互作用的新评估系统奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A new evaluation system for drug–microbiota interactions

The drug response phenotype is determined by a combination of genetic and environmental factors. The high clinical conversion failure rate of gene-targeted drugs might be attributed to the lack of emphasis on environmental factors and the inherent individual variability in drug response (IVDR). Current evidence suggests that environmental variables, rather than the disease itself, are the primary determinants of both gut microbiota composition and drug metabolism. Additionally, individual differences in gut microbiota create a unique metabolic environment that influences the in vivo processes underlying drug absorption, distribution, metabolism, and excretion (ADME). Here, we discuss how gut microbiota, shaped by both genetic and environmental factors, affects the host's ADME microenvironment within a new evaluation system for drug–microbiota interactions. Furthermore, we propose a new top-down research approach to investigate the intricate nature of drug–microbiota interactions in vivo. This approach utilizes germ-free animal models, providing foundation for the development of a new evaluation system for drug–microbiota interactions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.80
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Novel microbial modifications of bile acids and their functional implications The rheumatoid arthritis gut microbial biobank reveals core microbial species that associate and effect on host inflammation and autoimmune responses Akkermansia muciniphila administration ameliorates streptozotocin-induced hyperglycemia and muscle atrophy by promoting IGF2 secretion from mouse intestine iNAP 2.0: Harnessing metabolic complementarity in microbial network analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1